Accellta Ltd. specializes in the large-scale production of high-quality human embryonic and induced pluripotent stem cells, progenitors, and differentiated cells. Utilizing proprietary 3D suspension systems under feeder-free, adherent-free, and xeno-free conditions, Accellta offers custom-made solutions for drug discovery, regenerative medicine, and research. Their innovative technologies significantly reduce production time and costs, providing exceptional cell quality and scalability.